Open Access4CPS-149 Time of permanence in second or successive lines of treatment with anti-tnf drugs vs other biological drugs in patients with inflammatory arthropathies
Author(s) -
Marina Sáez Belló,
Pilar Llopis Salvià,
Marta Hermenegildo Caudevilla,
Jesús Bénavidès,
Mónica Climente Martí,
JJ Alegre Sancho
Publication year - 2018
Publication title -
section 4: clinical pharmacy services
Language(s) - English
Resource type - Conference proceedings
DOI - 10.1136/ejhpharm-2018-eahpconf.240
Subject(s) - medicine , psoriatic arthritis , ankylosing spondylitis , rheumatoid arthritis , drug , concomitant , retrospective cohort study , infliximab , adalimumab , biological drugs , pharmacotherapy , psoriasis , tumor necrosis factor alpha , pharmacology , immunology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom